The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to ...

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...

A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.

There is a consensus emerging that surgery is most appropriate for people with severe obesity for whom lifestyle ...

The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is ...

Lilly CEO Dave Ricks is confident in the ability of the company's pill to compete and is preparing for a "full launch" in the second quarter.

Mid-stage trial data showed Roche's experimental shot delivered weight loss on par with leading obesity treatments, ...

Louisiana ranks among the highest states nationally for childhood obesity, with some reports placing it as high as fourth, ...

The AACE has updated its guidance on obesity and adiposity-based chronic disease to reflect a focus on improving overall ...

Amgen is running a number of studies of its obesity drug, MariTide.

Researchers have quantified the role of obesity in common long-term conditions, showing for the first time the effect of ...